Sernova Corp.
Sernova Corp.
Your view on SVA.TO
Overview
What the company does, where it operates, and who runs it.
About Sernova Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan M. N. Rigby MBA
- Headquarters
- The Stiller Centre, London, ON, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan M. N. Rigby MBA
- Headquarters
- The Stiller Centre, London, ON, GB
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform.
The company was incorporated in 1998 and is headquartered in London, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sernova Corp., and the rating behind it. SVA.TO last traded at C$0.14; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sernova Corp.. Starting points for Sernova Corp.: EPS -C$0.03, beta 0.64 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sernova Corp.. Sernova Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sernova Corp.. Trailing twelve-month EPS for Sernova Corp. stands at -C$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sernova Corp.. Sernova Corp. has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sernova Corp. valued side by side against its closest peers. Sernova Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sernova Corp., and how their positions are changing. At a C$51.0M market value, institutional positions materially move Sernova Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sernova Corp. executives and directors. Shares of Sernova Corp. have traded between C$0.13 and C$0.26 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sernova Corp.. Sernova Corp. is a C$51.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sernova Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sernova Corp.. Coverage tracks Sernova Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.